Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsLaxmicotspin

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Lupin back on track, may clock 18-20% growth going ahead

      Lupin's Q2 numbers were in line with street estimates, with margins slightly higher. MD Nilesh Gupta believes the company is back on its growth trajectory and will post better numbers going forward.

    • Ranbaxy to drag; buy DRL, Glenmark; neutral on Lupin: Rathi

      He is positive on Dr Reddy mainly because the company is going to benefit significantly in FY14 and FY15 from the new launches and at the same time the margins will also be higher. He does not expect any major surprise coming in Lupins' quarterly result.

    • Lupin Q2 PAT seen up 29.3% at Rs 375.6 cr: ICICIdirect

      According to ICICIdirect.com, Lupin to report a 6.4 percent degrowth quarter-on-quarter (up 29.3 percent Y-o-Y) in net profit at Rs 375.6 crore.

    • Lupin Q2 net may rise 15% at Rs 316.8 cr: Motilal Oswal

      According to Motilal Oswal, Lupin may report a 4.9 percent degrowth quarter-on-quarter (up 15 percent Y-o-Y) in net profit at Rs 316.8 crore.

    • Rupee fall aided company's Q1 profits: Lupin

      In an interview to CNBC-TV18, Sharma credits the foreign exchange for about 2 percent EBITDA growth in the company‘s earnings.

    • Lupin hit by drug pricing; biz did well globally: Angel

      Sarabjit Kour Nangra of Angel Broking believes that India‘s drug pricing policy impacted Lupin‘s earnings for June quarter. The pharmaceutical major posted a 43 percent net profit year-on-year (YoY), but revenues rose lower-than-expected 10 percent YoY.

    • Lupin Q1: Analysts expect PAT to grow 33% at Rs 373 cr

      Lupin's revenues may increase by 19 percent on yearly basis to Rs 2,674 crore during April-June quarter. Previous quarter (Q4) was the 26th consecutive quarter of revenue growth of over 15 percent Y-o-Y.

    • Lupin Q1: Emkay expects PAT to rise 16% to Rs 325 cr: Emkay

      Emkay Equity Advisory expects Lupin to report a 20.5 percent degrowth quarter-on-quarter (rise of 15.7 percent year-on-year) in net profit at Rs 324.5 crore.

    • Lupin Q1 PAT seen up 37% at Rs 384 cr: KR Choksey

      KR Choksey expects Lupin to report a 6 percent degrowth quarter-on-quarter (rise of 37 percent year-on-year) in net profit at Rs 384 crore.

    • Indian pharmas gain on N America boost: Q4 earnings review

      CNBC-TV18‘s Archana Shukla reports that the pharma sector‘s fortunes in the January-March quarter were dictated by the US market while the sector's earnings were mixed.

    • Attention to margins, quality doubles Lupin Q4 net: MD

      Kamal Sharma, MD, Lupin Ltd says, in an interview to CNBC-TV18, that the attention to margins, quality and control on costs caused fourth-quarter net to double

    • Lupin Q4: Analysts expect 108% PAT growth at Rs 324 cr

      Healthcare firm Lupin will announce its fourth quarter (January-March) earnings on Wednesday. Analysts on an average expect the profit after tax to grow by 108.3 percent year-on-year to Rs 324 crore, according to CNBC-TV18 poll.

    • Pharma cos likely to post 21% EBITDA growth in Q4: MOST

      Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

    • See 23% margins by FY13 end; Indian biz at 18%: Lupin

      In an interview to CNBC-TV18, Kamal Sharma, managing director, Lupin gives his reaction on the company's positive Q3 results. The company's results beat expectations with itts profits jumping 43% to Rs 335 crore.

    • Lupin Q3: Analysts expect profit to grow 27% to Rs 299 cr

      Healthcare firm Lupin is set to declare its results for the third quarter of financial year 2012-13 on Thursday. Analysts on an average expect profit after tax of the company to grow by 27 percent year-on-year to Rs 299 crore in the quarter.

    • Lupin Q2: Analysts expect 5% growth in PAT YoY

      Drug producer Lupin's consolidated profit after tax is likely to go up by 4.7 percent year-on-year to Rs 279.3 crore in the second quarter of FY13.

    • Lupin Q2 revenues seen up 24% to Rs 2200 cr

      Drug producer Lupin's consolidated profit after tax is likely to go up by 4.7 percent year-on-year to Rs 279.3 crore in the second quarter of FY13.

    • Growth in quarter driven by generics: Lupin

      Kamal Sharma, MD, Lupin explains to CNBC-TV18 that the 44% growth in the topline was driven primarily by the excellent performance of generics, launch of new products in the US, Japan and India, and the recent signing of a pact to launch Novartis‘ Onbrez brand for asthama.

    • Lupin Q1 PAT seen up 27% to Rs 267 cr

      Drug producer Lupin's profit after tax is likely to grow by 27% year-on-year and 71.6% quarter-on-quarter to Rs 267 crore in the quarter ended June 2012.

    • Lupin Q1 revenues seen up 29% to Rs 2,026 cr

      Drug producer Lupin's profit after tax is likely to grow by 27% year-on-year and 71.6% quarter-on-quarter to Rs 267 crore in the quarter ended June 2012.

    • Lupin to focus on new product infusion in FY13

      Higher tax expenses led to a decline in consolidated net profit of pharma company, Lupin in the fourth quarter of FY12. The company posted a decline of 31% year-on-year to Rs 156 crore. However, net sales were up 25% between January-March at Rs 1,883.2 crore.

    • Lupin Q4 PAT seen up 17.8% at Rs 267 cr

      Pharmaceutical company Lupin is expected to report a growth of 17.9% year-on-year and 14% quarter-on-quarter in its profit after tax of Rs 267 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

    • Could exceed earlier outlined guidance: Lupin

      In an interview to CNBC-TV18, Dr Kamal K Sharma, managing director, Lupin said, the company will be able to maintain its performance during the year.

    • Lupin Q3 PAT seen up 4% to Rs 233 cr

      Lupin is expected to report a profit after tax of Rs 233 crore in the quarter ended December FY12, a moderate growth of 4% as compared to Rs 224 crore in a year ago quarter.

    • Q2 report card: Pharma sector posts encouraging numbers

      After a sluggish first quarter, pharma universe reported some encouraging numbers in the second quarter. This is with some support from stable growth in certain geographies but inflationary pressures taking a test on the other hand report CNBC-TV18's Archana Shukla.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347